A paper appearing in Proceedings of the National Academy of Sciences offers a strikingly simple answer to a longstanding ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Using CRISPR, multiomics, and machine learning, molecular biologist Larschan unravels the mysteries of the X chromosome.

Genome‑wide CRISPR screens in primary human T cells reveal human genes that promote or block HIV infection, uncovering potent ...

The human immunodeficiency virus (HIV), which is the cause of AIDS, is a master of deception, using just nine genes to hijack ...

A trio of common amino acids may hold the key to unlocking far more powerful gene therapies. Researchers found that adding ...

CRISPR is a breakthrough technology with humble origins. Scientists first discovered the powerful gene editor in bacteria that were using it as a weapon against invading viruses called phages. Phages ...

CRISPR Cas9 genome editing has transformed the way scientists approach gene therapy, acting like precise DNA scissors that can target and repair hereditary diseases at the genetic level. This ...

Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex Pharmaceuticals has a robust underlying business along with some exposure to ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death. The agency has ...